article thumbnail

What does the future of specialist distribution look like?

Fierce Pharma

The patient journey is evolving. How will specialty distribution keep up? Joining us on this episode of The Top Line is Jeff Beck, Chief Development Officer at BioCare. |

article thumbnail

Orchestrating Care in the New World of Distributive Access

MedCity News

The challenge with the emerging model of “distributive access” is that there isn’t any one individual or entity coordinating everything; patients are left to navigate their own care journeys. The post Orchestrating Care in the New World of Distributive Access appeared first on MedCity News.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Making Pharmaceuticals and Distributing Pharmaceuticals: April 23–24, 2024

PharmaTech

The conference intends to help attendees streamline their manufacturing and distribution procedures to improve patient outcomes.

article thumbnail

Benefits of blockchain in limiting counterfeit drug distribution

European Pharmaceutical Review

Additionally, real-time access to data is also available to patients to go through their clinical trials, as well as sponsors, which reduces the cost of trials. The post Benefits of blockchain in limiting counterfeit drug distribution appeared first on European Pharmaceutical Review. In conclusion, Kordestani et al.

article thumbnail

The New Clinical Trial Supply Chain: Resilient, Flexible, and Patient-Centric

An increasing number of sponsors are seeking enhanced flexibility in their supply chains to address a variety of clinical supply challenges, including patient demand and reducing delays.

article thumbnail

Roche condemns 'act of counterfeiting' as authorities in Pakistan crack down on unapproved Avastin use

Fierce Pharma

After several diabetic patients received a sham version of Roche's Avastin and lost their sight, the Drug Regulatory Authority of Pakistan (DRAP) is halting the sale or distribution of the drug unt | Authorities in Pakistan are investigating the use of altered versions of Roche's Avastin after several diabetic patients who received a sham (..)

article thumbnail

Capricor and Nippon Shinyaku partner for DMD therapy distribution in Japan

Pharmaceutical Technology

Capricor Therapeutics and Japanese pharmaceutical firm Nippon Shinyaku have entered a collaboration for exclusively commercialising and distributing the former’s CAP-1002 to treat duchenne muscular dystrophy (DMD) in Japan.

article thumbnail

Making the Case for Case Management for Cell and Gene Therapies

Deviations from the intended supply chain can delay timelines and affect these high value products, which can be detrimental to budgets, but more importantly can have dire effects on the patients whose lives depend on receiving these critical doses safely and on time.